UA117686C2 - Солі 1-(3-метил-2-оксо-2,3-дигідро-1,3-бензоксазол-6-іл)-2,4-діоксо-3-[(1r)-4-(трифторометил)-2,3-дигідро-1н-інден-1-іл]-1,2,3,4-тетрагідропіримідин-5-карбонової кислоти - Google Patents

Солі 1-(3-метил-2-оксо-2,3-дигідро-1,3-бензоксазол-6-іл)-2,4-діоксо-3-[(1r)-4-(трифторометил)-2,3-дигідро-1н-інден-1-іл]-1,2,3,4-тетрагідропіримідин-5-карбонової кислоти

Info

Publication number
UA117686C2
UA117686C2 UAA201606202A UAA201606202A UA117686C2 UA 117686 C2 UA117686 C2 UA 117686C2 UA A201606202 A UAA201606202 A UA A201606202A UA A201606202 A UAA201606202 A UA A201606202A UA 117686 C2 UA117686 C2 UA 117686C2
Authority
UA
Ukraine
Prior art keywords
dihydro
salts
tetrahydropyrimidin
trifluormethyl
benzoxazol
Prior art date
Application number
UAA201606202A
Other languages
English (en)
Inventor
Брітта Оленік
Біргіт Кайль
Мартін-Хольгер Хінц
Шанталь Фюрстнер
Маріо Еске
Єнс Аккерштафф
Original Assignee
Байєр Фарма Акцієнгезелльшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байєр Фарма Акцієнгезелльшафт filed Critical Байєр Фарма Акцієнгезелльшафт
Publication of UA117686C2 publication Critical patent/UA117686C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Винахід належить до нових солей 1-(3-метил-2-оксо-2,3-дигідро-1,3-бензоксазол-6-іл)-2,4-діоксо-3-[(1R)-4-(трифторметил)-2,3-дигідро-1Н-інден-1-іл]-1,2,3,4-тетрагідропіримідин-5-карбонової кислоти формули (І), особливо до солей амінокислот, таких як сіль лізину, й до солей лужних металів, таких як сіль натрію й сіль калію, до способу їх одержання, до лікарських препаратів, що включають їх, й їх застосування для боротьби із захворюваннями.
UAA201606202A 2013-11-08 2014-11-05 Солі 1-(3-метил-2-оксо-2,3-дигідро-1,3-бензоксазол-6-іл)-2,4-діоксо-3-[(1r)-4-(трифторометил)-2,3-дигідро-1н-інден-1-іл]-1,2,3,4-тетрагідропіримідин-5-карбонової кислоти UA117686C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13192177 2013-11-08
PCT/EP2014/073801 WO2015067652A1 (de) 2013-11-08 2014-11-05 Salze von 1 -(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluormethyl)-2,3-dihydro-1h-inden-1 -yl]-1,2,3,4-tetrahydropyrimidin-5-carbonsäure

Publications (1)

Publication Number Publication Date
UA117686C2 true UA117686C2 (uk) 2018-09-10

Family

ID=49552231

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201606202A UA117686C2 (uk) 2013-11-08 2014-11-05 Солі 1-(3-метил-2-оксо-2,3-дигідро-1,3-бензоксазол-6-іл)-2,4-діоксо-3-[(1r)-4-(трифторометил)-2,3-дигідро-1н-інден-1-іл]-1,2,3,4-тетрагідропіримідин-5-карбонової кислоти

Country Status (33)

Country Link
US (1) US9926305B2 (uk)
EP (1) EP3066097B1 (uk)
JP (1) JP6446051B2 (uk)
KR (1) KR102351418B1 (uk)
CN (1) CN105658647B (uk)
AP (1) AP2016009181A0 (uk)
AU (1) AU2014345599B2 (uk)
BR (1) BR112016010253A8 (uk)
CA (1) CA2929780C (uk)
CL (1) CL2016001096A1 (uk)
CY (1) CY1119520T1 (uk)
DK (1) DK3066097T3 (uk)
EA (1) EA033132B1 (uk)
ES (1) ES2645480T3 (uk)
HK (1) HK1222171A1 (uk)
HR (1) HRP20171603T1 (uk)
HU (1) HUE035021T2 (uk)
IL (1) IL245407B (uk)
LT (1) LT3066097T (uk)
MA (1) MA39020A1 (uk)
ME (1) ME02907B (uk)
MX (1) MX366848B (uk)
MY (1) MY190108A (uk)
NO (1) NO3066097T3 (uk)
PH (1) PH12016500853A1 (uk)
PL (1) PL3066097T3 (uk)
PT (1) PT3066097T (uk)
RS (1) RS56509B1 (uk)
SA (1) SA516371082B1 (uk)
SI (1) SI3066097T1 (uk)
TN (1) TN2016000170A1 (uk)
UA (1) UA117686C2 (uk)
WO (1) WO2015067652A1 (uk)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3338780A1 (de) 2016-12-20 2018-06-27 Bayer Pharma Aktiengesellschaft Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind
US20200230136A1 (en) * 2017-04-27 2020-07-23 Bayer Aktiengesellschaft Selective adrenoreceptor alpha2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad)
WO2022135502A1 (zh) * 2020-12-25 2022-06-30 广东东阳光药业有限公司 多取代的尿嘧啶衍生物及其用途
AU2023251136A1 (en) * 2022-04-05 2024-10-17 Bayer Aktiengesellschaft Inhibitors of chymase for use in the selective resolution of thrombi in thrombotic or thromboembolic disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001295952A1 (en) * 2000-10-19 2002-04-29 Nippon Kayaku Kabushiki Kaisha Novel remedies or preventives for angiostenosis
AT511788A1 (de) 2011-07-29 2013-02-15 Georg Dr Gaul Vorrichtung zur vorgebbaren anordnung eines stents
NZ700067A (en) * 2012-03-05 2016-07-29 Gratuk Technologies Pty Ltd Dietary supplement
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
CA2929763A1 (en) * 2013-11-08 2015-05-14 Bayer Pharma Aktiengesellschaft Substituted uracils as chymase inhibitors

Also Published As

Publication number Publication date
EA033132B1 (ru) 2019-08-30
JP2016535096A (ja) 2016-11-10
HRP20171603T1 (hr) 2017-12-01
KR102351418B1 (ko) 2022-01-17
IL245407A0 (en) 2016-06-30
AP2016009181A0 (en) 2016-04-30
BR112016010253A8 (pt) 2021-06-22
CL2016001096A1 (es) 2016-12-23
NZ719532A (en) 2021-06-25
MX2016005971A (es) 2016-08-11
PL3066097T3 (pl) 2018-01-31
ME02907B (me) 2018-04-20
LT3066097T (lt) 2018-02-12
PH12016500853B1 (en) 2016-06-20
EP3066097A1 (de) 2016-09-14
KR20160078980A (ko) 2016-07-05
HK1222171A1 (zh) 2017-06-23
MX366848B (es) 2019-07-26
NO3066097T3 (uk) 2018-01-13
CY1119520T1 (el) 2018-03-07
DK3066097T3 (da) 2017-11-06
WO2015067652A1 (de) 2015-05-14
SI3066097T1 (sl) 2017-12-29
US20160289220A1 (en) 2016-10-06
CN105658647A (zh) 2016-06-08
JP6446051B2 (ja) 2018-12-26
EA201600381A1 (ru) 2016-10-31
SA516371082B1 (ar) 2019-05-16
MA39020A1 (fr) 2017-04-28
CA2929780A1 (en) 2015-05-14
ES2645480T3 (es) 2017-12-05
AU2014345599A1 (en) 2016-05-19
HUE035021T2 (en) 2018-03-28
PH12016500853A1 (en) 2016-06-20
US9926305B2 (en) 2018-03-27
TN2016000170A1 (en) 2017-10-06
EP3066097B1 (de) 2017-08-16
AU2014345599B2 (en) 2019-02-14
MY190108A (en) 2022-03-29
CA2929780C (en) 2022-03-22
PT3066097T (pt) 2017-11-10
RS56509B1 (sr) 2018-02-28
BR112016010253A2 (pt) 2017-08-08
IL245407B (en) 2019-10-31
CN105658647B (zh) 2019-09-06

Similar Documents

Publication Publication Date Title
EA201592200A1 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
MX2015009591A (es) Amidas como moduladores de canales de sodio.
NZ710111A (en) Quinoline and quinoxaline amides as modulators of sodium channels
EA030383B9 (ru) Бициклически замещённые урацилы, способы их получения, их применение, лекарственное средство и способ лечения с их применением
PH12016500853A1 (en) Salts of 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)- 4-(trifluormethyl)-2,3-dihydro-1h-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carboxylic acid
BR112014028042A2 (pt) inibidores de nampt
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
PE20140966A1 (es) Quinazolincarboxamida azetidinas
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
EA201490045A1 (ru) Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении
EA201270176A1 (ru) Производные тазаротена
EA201491878A8 (ru) Замещенные ксантиновые производные
ECSP13013043A (es) Composición oral líquida que comprende sodio divalproex y proceso para preparar la misma
TH1601002185A (th) เกลือแบบใหม่ของ 1-(3-เมธิล-2-ออกโซ-2,3-ไดไฮโดร-1,3-เบนซอกซาโซล-6-อิล)-2,4- ไดออกโซ-3-[(1r)-4-(ไตรฟลูออโรเมธิล)-2,3-ไดไฮโดร-1h-อินดิน-1-อิล]-1,2,3,4- เตตระไฮโดรไพริมิดีน-5-คาร์บอกซิลิกแอซิดและการใช้เกลือดังกล่าว
TN2013000150A1 (en) Co-crystals and salts of ccr3-inhibitors
MX2012013055A (es) Un procedimiento mejorado para purificar el complejo de cloruro de benzalconio-dialil oxido de disulfuro modificado y usos.
PL410369A1 (pl) Nowe pochodne peptydowe, sposób ich otrzymywania, kompozycja farmaceutyczna, kompozycja dezynfekująca oraz zastosowanie i zestaw
IN2014MU01178A (uk)
EA201790231A1 (ru) Профилактическое или терапевтическое средство для лечения болезней заднего сегмента глаза
UA103803C2 (en) Use of 1-methoxycarbonylmethyl-7-bromo-5-phenyl-3-arylamino-1,2-dihydro-3h-1,4-benzodiazepine-ones as analgetic agents
MX2015006807A (es) Metodo de preparacion de formas cristalinas de la 4-(ciclopropilmetoxi)-n-(3,5-dicloro-1-oxidopiridin-4-il)-5-metox ipiridin-2-carboxamida y sus formas cristalinas.
MY166773A (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
PL397924A1 (pl) Zastosowanie medyczne substancji 5-(3-chlorofenylo)-4-(4-fluorofenylo)-2,4-dihydro-3H-1,2,4-triazolo-3-tionu
PL399011A1 (pl) Pochodna 1,2,4-triazolu - 5-(3-chlorofenylo)-4-heksylo-2,4-dihydro-3H-1,2,4-triazolo-3-tion, sposób jej wytwarzania i jej zastosowanie medyczne